Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Emergent BioSolutions : Chardan Upgrades Emergent BioSolutions to Buy From Neutral, Maintains $112 Price Target

02/24/2021 | 07:48am EDT


ę MT Newswires 2021
All news about EMERGENT BIOSOLUTIONS INC.
10/15EMERGENT BIOSOLUTIONS : Emergency BioSolutions Doses First Patient in Phase 3 Trial of Vac..
MT
10/15EMERGENT BIOSOLUTIONS : Announces Initiation of Pivotal Phase 3 Study Evaluating the Safet..
AQ
10/01EMERGENT BIOSOLUTIONS : Unit Gets Additional AV7909 Dose Order From BARDA -- Shares Jump
MT
10/01EMERGENT BIOSOLUTIONS : Material Definitive Agreement (Form 8-K)
PU
10/01EMERGENT BIOSOLUTIONS INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
09/21SHUMAN, GLENN & STECKER : Investigates Emergent BioSolutions, Inc.
BU
09/14Calgary firm advances new trial, manufacturing of mRNA vaccine for COVID-19
AQ
09/14EMERGENT BIOSOLUTIONS : Signs Five-Year, $90 Million Contract With Providence Therapeutics
MT
09/14EMERGENT BIOSOLUTIONS : Secures Multi-Year Development and Manufacturing Agreement with Pr..
AQ
09/14Emergent BioSolutions Inc. Secures Multi-Year Development and Manufacturing Agreement w..
CI
More news
Analyst Recommendations on EMERGENT BIOSOLUTIONS INC.
More recommendations
Financials (USD)
Sales 2021 1 797 M - -
Net income 2021 356 M - -
Net Debt 2021 152 M - -
P/E ratio 2021 7,88x
Yield 2021 -
Capitalization 2 722 M 2 722 M -
EV / Sales 2021 1,60x
EV / Sales 2022 1,54x
Nbr of Employees 2 200
Free-Float 88,6%
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 50,69 $
Average target price 83,33 $
Spread / Average Target 64,4%
EPS Revisions
Managers and Directors
Robert G. Kramer President, Chief Executive Officer & Director
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Fuad El Hibri Executive Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Karen L. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EMERGENT BIOSOLUTIONS INC.-42.58%2 722
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657